Clinical Trial Update: Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec) [Phase 2]

View source ↗

Summary

Phase II trial of decitabine in patients with chronic myeloid leukemia in the accelerated phase who are refractory to imatinib mesylate has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Dacogen (decitabine)
• Gleevec (Imatinib)

Snippet

Sponsor: Astex Pharmaceuticals, Inc. | Conditions: Chronic Myelogenous Leukemia | Phase 2 | Status: COMPLETED